Metabolic Syndrome and Colorectal Cancer: Exploring the Link Between Metabolic Dysregulation and Tumor Features

Background: Metabolic syndrome (MetS)—a cluster of obesity, insulin resistance, dyslipidemia, and hypertension—is a known risk factor for colorectal cancer (CRC) and may influence tumor progression through hyperinsulinemia, chronic inflammation, oxidative stress, and genomic instability. This study aims to assess differences in tumor characteristics between CRC patients with and without MetS in Egypt, which could enhance risk stratification, treatment, and prognosis. Methods: This prospective cross-sectional study was conducted at Maadi Military Hospital’s Medical Oncology Department on 72 newly diagnosed CRC patients (≥18 years). Patients with double primary tumors were excluded. Data collection included medical history, clinical examination, histopathology, blood tests, and imaging. MetS was assessed based on obesity, diabetes, hypertension, dyslipidemia, and cardiovascular disease. The primary objective was to determine MetS prevalence among CRC patients and its association with CRC stage, characteristics, and aggression. Results: Among 72 CRC patients (51.4% males, 48.6% females, mean age 68.64 ± 5.38 years), MetS was present in 41.67%. MetS patients had significantly higher CA19-9 and CEA tumor markers (p < 0.001). Hypertension was linked to advanced CRC stages (p = 0.043), while MetS correlated with poorly differentiated tumors (p = 0.001). Logistic regression identified waist circumference, diabetes, cardiovascular disease, lipid levels, fasting blood glucose, and tumor markers as MetS predictors. Conclusion: MetS was present in 41.67% of CRC patients and was associated with tumor differentiation and aggression. Tumor markers and MetS components were key predictors, highlighting MetS as a potential factor in CRC progression.